Generic placeholder image

Current Nanomaterials

Author(s): Amand Alekhya and Abbaraju Krishna Sailaja*

DOI: 10.2174/2405461507666220831093135

DownloadDownload PDF Flyer Cite As
Formulation and Evaluation of Letrozole Nanosuspension By Probe Sonication Method using Box-behnken Design

Page: [266 - 279] Pages: 14

  • * (Excluding Mailing and Handling)

Abstract

Background: Letrozole (LTZ) is an aromatase inhibitor used to treat hormonally positive breast cancer in postmenopausal women. Letrozole is categorized as a BCS class I drug. It has poor water solubility, rapid metabolism and a range of side effects.

Objective: Nanosuspension is a technique that enhances the drug's solubility and bioavailability, resulting in a faster start of the effect. The present study aimed to formulate nanosuspension using probe sonication method to enhance the solubility of Letrozole using poloxamer-188 as a stabilizer. The formulation scheme was generated using Box-Behnken design, a statistical tool for the design of experiments (DOE).

Results: By employing the probe sonication method, a total of seventeen formulations were performed for letrozole nanosuspension as suggested by Box-Behnken design. The selected formulations are characterized for particle size and zeta potential. The formulations were checked on the bias percentage between the predicted and observed values and evaluated for drug content and in vitro dissolution study. The formulation was optimized using Box-Behnken design based on in vitro cumulative drug release. Among all the formulations, NS4 (500 mg poloxamer-188, 100mg Letrozole and sonication time of 20 mints) was considered best with a minimum particle size of 923.5 nm, Zeta potential value of -28.7 mV, 96.36% of drug content and 94.02% of drug release within 2 hours. Solubility was determined by the shake flask method. The solubility of the pure drug was found to be only 10%. The solubility studies performed for the optimized formulation of NS4 showed that the solubility has enhanced up to 90% compared to pure drugs.

Conclusion: Thus, the present results revealed that Letrozole nanosuspension solubility has enhanced up to 90% compared to pure drugs using poloxamer-188 as a stabilizer.

Keywords: Letrozole, Nanosuspension, Probe, sonication method, Box-Behnke, n design

Graphical Abstract

[1]
Ingvarsson S. Breast cancer: Introduction. Semin Cancer Biol 2001; 11(5): 323-6.
[http://dx.doi.org/10.1006/scbi.2001.0381]
[2]
Eccles SA, Aboagye EO, Ali S, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res 2013; 15(5): R92.
[http://dx.doi.org/10.1186/bcr3493] [PMID: 24286369]
[3]
Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J Clin 2014; 64(3): 186-94.
[http://dx.doi.org/10.3322/caac.21225] [PMID: 24647877]
[4]
Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta analysis of individual participant data. Lancet 2013; 381(9880): 1827-34.
[http://dx.doi.org/10.1016/S0140-6736(13)60140-3] [PMID: 23639488]
[5]
Goss PE, Ingle JN, Alés MJE, et al. Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 2011; 364(25): 2381-91.
[http://dx.doi.org/10.1056/NEJMoa1103507] [PMID: 21639806]
[6]
Simpson D, Curran MP, Perry CM. Letrozole. Drugs 2004; 64(11): 1213-30.
[http://dx.doi.org/10.2165/00003495-200464110-00005] [PMID: 15161328]
[7]
Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001; 37(12): 1510-3.
[http://dx.doi.org/10.1016/S0959-8049(01)00155-1] [PMID: 11506958]
[8]
What is nanotechnology? National Nanotechnology Initiative. Available from: https://www.nano.gov/nanotech-101/what/ definition
[9]
Applications of nanotechnology. National Nanotechnology Initiative. Available from: https://www.nano.gov/about-nanotechnology/applications-nanotechnology
[10]
Chingunpituk J. Nanosuspension technology for drug delivery. Walailak J Sci Technol 2007; 4(2): 139-53.
[11]
Eldin AB. General introduction to design of experiments (DOE). In: Dr. Isin Akyar, Ed. Wide spectra of quality control INTEC. 2011; pp. 21-6. Available from: https://www.intechopen.com/chapters/23727
[12]
Zhang J, Xie Z, Zhang N, Zhong J. Nanosuspension drug delivery system: Preparation, characterization, postproduction processing, dosage form, and application Nanostruct Drug Deliv. Elsevier 2017; pp. 413-43.
[http://dx.doi.org/10.1016/B978-0-323-46143-6.00013-0]
[13]
Lakshmi P, Kumar GA. Nanosuspension technology: A review. Int J Pharma Sci 2010; 2(4): 35-40.
[14]
Singh S, Vaidya Y, Gulati M, Bhattacharya S, Garg V, Pandey N. Nanosuspension: Principles, perspectives and practices. Curr Drug Deliv 2016; 13(8): 1222-46.
[http://dx.doi.org/10.2174/1567201813666160101120452] [PMID: 26721266]
[15]
Agrawal YK, Patel VR. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res 2011; 2(2): 81-7.
[http://dx.doi.org/10.4103/2231-4040.82950] [PMID: 22171298]
[16]
Goel S, Sachdeva M, Agarwal V. Nanosuspension technology: Recent patents on drug delivery and their characterizations. Recent Pat Drug Deliv Formul 2019; 13(2): 91-104.
[http://dx.doi.org/10.2174/1872211313666190614151615] [PMID: 31203813]
[17]
Arunkumar N, Deecaraman M, Rani C. Nanosuspension technology and its applications in drug delivery. Asian J Pharm 2014; 3(3)
[18]
Krishna KB, Prabhakar C. A review on nanosuspensions in drug delivery. Int J Pharma Bio Sci 2011; 2(1): 549-58.
[19]
Verma S, Burgess D. Solid nanosuspensions: The emerging technology and pharmaceutical applications as nanomedicine. In: Kulshreshtha A, Singh O, Wall G, Eds. Pharmaceutical Suspensions. New York, NY: Springer 2010; pp. 285-318.
[http://dx.doi.org/10.1007/978-1-4419-1087-5_10]
[20]
Ferreira SLC, Bruns RE, Ferreira HS, et al. Box Behnken design: An alternative for the optimization of analytical methods. Anal Chim Acta 2007; 597(2): 179-86.
[http://dx.doi.org/10.1016/j.aca.2007.07.011] [PMID: 17683728]
[21]
Eriksson L, Johansson E, Kettaneh WN, Wikström C, Wold S. Design of experiments. Principles and applications, Learn ways. AB, Stockholm 2000. J Chemometrics 2001; 15(5): 495-6.
[http://dx.doi.org/analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/cem.686]
[22]
N Politis S. Colombo P, Colombo G, M Rekkas D. Design of Experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm 2017; 43(6): 889-901.
[http://dx.doi.org/10.1080/03639045.2017.1291672] [PMID: 28166428]
[23]
Rowe RC, Sheskey P, Quinn M. Handbook of pharmaceutical excipients. (6th ed.). Pharmaceutical Press 2009; pp. 506-9.
[24]
Hussain CM, Ed. Handbook on Miniaturization in Analytical Chemistry: Application of Nanotechnology. Chaudhery H, Ed. Elsevier 2020.
[25]
Jacobs C, Kayser O, Müller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm 2000; 196(2): 161-4.
[http://dx.doi.org/10.1016/S0378-5173(99)00412-3] [PMID: 10699709]
[26]
Dzakwan M, Pramukantoro GE, Mauludin R, Wikarsa S. Formulation and characterization of fisetin nanosuspension. IOP Conf Series Mater Sci Eng 2017; 259(1): 012016.
[http://dx.doi.org/10.1088/1757-899X/259/1/012016]
[27]
Dibaei M, Rouini MR, Sheikholeslami B, Gholami M, Dinarvand R. The effect of surface treatment on the brain delivery of curcumin nanosuspension: In vitro and in vivo studies. Int J Nanomedicine 2019; 14: 5477-90.
[http://dx.doi.org/10.2147/IJN.S199624] [PMID: 31409999]
[28]
Jadhav PA, Yadav AV. Design, development and characterization of ketorolac tromethamine polymeric nanosuspension. Ther Deliv 2019; 10(9): 585-97.
[http://dx.doi.org/10.4155/tde-2019-0045] [PMID: 31581882]
[29]
Taneja S, Shilpi S, Khatri K. Formulation and optimization of efavirenz nanosuspensions using the precipitation ultrasonication technique for solubility enhancement. Artif Cells Nanomed Biotechnol 2016; 44(3): 978-84.
[PMID: 25724312]
[30]
Goel S, Agarwal V, Sachdeva M. Development and characterization of oral nanosuspension using esomeprazole magnesium trihydrate. Nanosci Nanotechnol Asia 2020; 10(6): 909-17.
[http://dx.doi.org/10.2174/2210681209666191111113850]
[31]
Singare DS, Marella S, Gowthamrajan K, Kulkarni GT, Vooturi R, Rao PS. Optimization of formulation and process variable of nanosuspension: An industrial perspective. Int J Pharm 2010; 402(1-2): 213-20.
[http://dx.doi.org/10.1016/j.ijpharm.2010.09.041] [PMID: 20933066]
[32]
Jadhav P, Yadav A. Formulation, optimization, and in vitro evaluation of polymeric nanosuspension of flurbiprofen. Asian J Pharm Clin Res 2019; 12(11): 183-91.
[http://dx.doi.org/10.22159/ajpcr.2019.v12i11.35670]
[33]
Nagaraj K, Narendar D, Kishan V. Development of olmesartan medoxomil optimized nanosuspension using the Box–Behnken design to improve oral bioavailability. Drug Dev Ind Pharm 2017; 43(7): 1186-96.
[http://dx.doi.org/10.1080/03639045.2017.1304955] [PMID: 28271908]
[34]
Kassem MAA, ElMeshad AN, Fares AR. Enhanced solubility and dissolution rate of lacidipine nanosuspension: Formulation via antisolvent sonoprecipitation technique and optimization using Box–Behnken design. AAPS PharmSciTech 2017; 18(4): 983-96.
[http://dx.doi.org/10.1208/s12249-016-0604-1] [PMID: 27506564]
[35]
Hao J, Gao Y, Zhao J, et al. Preparation and optimization of resveratrol nanosuspensions by antisolvent precipitation using Box-Behnken design. AAPS PharmSciTech 2015; 16(1): 118-28.
[http://dx.doi.org/10.1208/s12249-014-0211-y] [PMID: 25209687]